Compare Ascendis Pharma A/S (ASND) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Canopy Growth Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Canopy Growth Corp trades at $0.97 (market cap $407.38M). The key difference: Ascendis Pharma A/S is far larger — about 43.5× Canopy Growth Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| ASND | CGC | |
|---|---|---|
Market Cap | $17.74B | $407.38M |
Sector | Health | Health |
52-Week High | $277.18 | $1.92 |
52-Week Low | $163.32 | $0.86 |
Enterprise Value | $18.11B | $346.82M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Canopy Growth (CGC) trades at $0.97, down 0.28% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses. Cash flow remains negative, but the balance sheet improved with a debt-to-asset ratio of 33.13% in 2025. Analyst sentiment is divided, with 33% buy ratings amid ongoing profitability challenges and potential reverse stock split discussions.
The outlook for CGC hinges on achieving profitability and navigating regulatory hurdles, with projected revenue growth to $285 million in 2026 offering a potential catalyst. Key risks include persistent losses, high debt, and Nasdaq compliance concerns, while institutional interest remains cautious. Investors should weigh the speculative turnaround potential against significant financial and operational headwinds in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
